Giovanni Cigliana
20 Papers
47 Citations
Giovanni Cigliana is an academic researcher. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 7, co-authored 20 publications.
Chat about Author
Papers
Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis.
Chiara Mandoj,Rosaria Renna,Domenico Plantone,Isabella Sperduti,Giovanni Cigliana,Laura Conti,Tatiana Koudriavtseva +6 more
TL;DR: The hypothesis that both thrombogenic and neurodegenerative mechanisms associated with an abnormal cholesterol homeostasis might contribute to MS progression is supported.
26
Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells
Valeria Catena,Tiziana Bruno,Francesca De Nicola,Frauke Goeman,Matteo Pallocca,Simona Iezzi,Cristina Sorino,Giovanni Cigliana,Aristide Floridi,Giovanni Blandino,Maurizio Fanciulli +10 more
TL;DR: It is found that Deptor plays an important role in the maintenance of the ER network, sustaining the expression of several genes involved in this pathway, and induces ER stress and synergizes the effect of the proteasome inhibitor bortezomib (Bz) in MM cells.
Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study
Manuela Spagnuolo,Manuela Costantini,Mariaconsiglia Ferriero,Marco Varmi,Isabella Sperduti,Giulia Regazzo,Lucia Cicchillitti,Ana Belén Díaz Méndez,Giovanni Cigliana,Vincenzo Pompeo,Andrea M. Russo,Valentina Laquintana,Riccardo Mastroianni,Giulia Piaggio,Umberto Anceschi,Aldo Brassetti,A.M. Bove,Gabriele Tuderti,Rocco Simone Flammia,Michele Gallucci,Giuseppe Simone,Maria Giulia Rizzo +21 more
TL;DR: Urinary let-7c cluster evaluation may improve prognosis, identifying patients at risk of progression and addressing early radical treatment, and a benefit was evident for patients with a PFS probability > 20%.
19
Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma.
Marialuisa Appetecchia,Aurela Meçule,Giuseppe Pasimeni,Concetta V Iannucci,Piero De Carli,Roberto Baldelli,Agnese Barnabei,Giovanni Cigliana,Isabella Sperduti,Michele Gallucci +9 more
TL;DR: It is shown that ChromograninA levels correlated to NE differentiation and possible aggressiveness of PC could complement PSA in selecting more aggressive PC cases, particularly in the presence of a higher Gleason score.
Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial
Irene Terrenato,Francesca Sperati,Felice Musicco,Anna F. Pozzi,Annunziata di Turi,Mauro Caterino,Elisabetta de Lutio di Castelguidone,Sergio Venanzio Setola,Massimo Bellomi,Massimo Bellomi,Carlo E. Neumaier,Laura Conti,Giovanni Cigliana,Roberta Merola,Anna Antenucci,Giulia Orlandi,Antonio Giordano,Antonio Giordano,Maddalena Barba,Stefano Canitano +19 more
TL;DR: The results suggest a more favorable safety profile of iodixanol versus iopromide in cancer patients with an estimated glomerular filtration rate (eGFR) >60 ml/min, and an adequate sized trials with similar design are warranted to confirm the findings.
14